This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Trevena’s 8K filing here.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Featured Stories
- Five stocks we like better than Trevena
- What is Put Option Volume?
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 11/4 – 11/8
- How to Use the MarketBeat Dividend Calculator
- Trump’s Return: Which Sectors Will Benefit Most?
